KCNH2 and cancer: Overall, the scDb–hERG1–β1 antibody could be used as a potential new treatment for cancer patients and as an early molecular diagnostic marker, thus configured as one of the first examples of companion diagnostics targeting ion channels ([123], unpublished data).